BURP3 Antibody

What is BUB3 protein and why is it important in research applications?

BUB3 is a crucial component of the mitotic spindle assembly checkpoint that ensures accurate chromosome segregation during cell division. Its primary function involves monitoring proper attachment of chromosomes to the mitotic spindle, preventing premature anaphase onset until all chromosomes are properly aligned. Dysregulation of BUB3 has been linked to chromosomal instability and tumorigenesis, highlighting its importance in cancer research . The protein consists of 328 amino acids in humans (NP_004716.1) and contains multiple WD40 repeat domains that facilitate protein-protein interactions essential for its checkpoint function . BUB3 research provides insights into potential therapeutic targets for cancer treatment and enhances our understanding of cell division error mechanisms. Experimental applications typically include immunoprecipitation assays to study protein interactions, immunofluorescence to visualize subcellular localization, and Western blotting to quantify expression levels.

Which sample types and species show confirmed reactivity with BUB3 antibodies?

BUB3 antibodies demonstrate strong cross-reactivity across multiple species and sample types, facilitating comparative studies. Species reactivity has been confirmed for human, mouse, and rat samples, with the antibody recognizing conserved epitopes within the BUB3 protein structure . This cross-reactivity enables consistent experimental approaches across different model systems. Positive reactivity has been specifically confirmed in multiple cell lines and tissue samples including:

Researchers should note that antibody performance may vary slightly between species, requiring optimization of protocols when transitioning between different model systems. For novel sample types, preliminary validation experiments are recommended .

What is the molecular basis for BUB3 antibody recognition?

The BUB3 polyclonal antibody recognition is based on specific binding to epitopes within a recombinant fusion protein corresponding to amino acids 1-328 of human BUB3 (NP_004716.1) . This sequence encompasses the complete BUB3 protein, containing multiple WD40 repeat domains that form a seven-bladed beta-propeller structure. The antibody recognition depends on the three-dimensional conformation of these domains, which can be affected by experimental conditions such as denaturation during Western blotting procedures. The full amino acid sequence recognized by the antibody is:

MTGS NEFK LNQP PEDG ISSV KFSP NTSQ FLLV SSWD TSVR LYDV PANS MRLK YQHT GAVL DCAF YDPT HAWS GGLD HQLK MHDL NTDQ ENLV GTHD APIR CVEY CPEV NVMV TGSW DQTV KLWD PRTP CNAG TFSQ PEKV YTLS VSGD RLIV GTAG RRVL VWDL RNMG YVQQ RRES SLKY QTRC IRAF PNKQ GYVL SSIE GRVA VEYL DPSP EVQK KKYA FKCH RLKE NNIE QIYP VNAI SFHN IHNT FATG GSDG FVNI WDPF NKKR LCQF HRYP TSIA SLAF SNDG TTLA IASS YMYE MDDT EHPE DGIF IRQV TDAE TKPK SPCT

Understanding this sequence recognition is critical for interpreting experimental results, particularly when designing blocking peptides or determining antibody cross-reactivity with related proteins.

How can researchers optimize Western blotting protocols for BUB3 detection?

Western blotting for BUB3 detection requires specific optimization steps to ensure reliable and reproducible results. Protocol optimization should begin with sample preparation: cells should be lysed in buffer containing protease inhibitors to prevent BUB3 degradation, and phosphatase inhibitors when studying phosphorylation status. For BUB3 detection (37 kDa), resolving gels of 10-12% polyacrylamide provide optimal separation. The recommended antibody dilution range of 1:500-1:2000 should be tested in preliminary experiments to determine optimal signal-to-noise ratio for specific sample types .

Critical methodological considerations include:

• Blocking solution: 5% non-fat dry milk in TBST is typically effective, but BSA may yield better results for phospho-specific detection

• Primary antibody incubation: Overnight at 4°C produces optimal results with less background

• Washing steps: At least 3×10 minutes with TBST to minimize background

• Positive controls: Include lysates from MCF7, HL-60, or HeLa cells as validated positive controls

• Loading controls: Include β-actin or GAPDH to normalize BUB3 expression levels

• Stripping and reprobing: Mild stripping buffers are recommended if reprobing is necessary

Researchers should validate detection specificity by including a blocking peptide control and demonstrating the expected molecular weight band (37 kDa). For quantitative analysis, ensure exposure times remain in the linear range of detection.

What experimental approaches can elucidate BUB3's role in chromosomal instability and cancer?

Investigating BUB3's role in chromosomal instability and cancer requires multifaceted experimental approaches. BUB3 dysregulation has been directly linked to chromosomal instability and tumorigenesis , necessitating sophisticated experimental designs to elucidate these mechanisms.

A comprehensive experimental strategy should include:

• Expression analysis: Compare BUB3 protein levels between normal and cancer tissues/cell lines using validated antibodies with Western blotting and immunohistochemistry. Correlation analysis between BUB3 expression and clinical parameters provides translational relevance.

• Loss-of-function studies: siRNA or CRISPR-Cas9 mediated BUB3 knockdown/knockout followed by:

  • Mitotic index measurement (phospho-histone H3 staining)

  • Chromosome spread analysis to quantify aneuploidy

  • Live-cell imaging to track chromosome segregation errors

  • Spindle assembly checkpoint functionality assays with nocodazole treatment

• Protein interaction studies: Immunoprecipitation with BUB3 antibody followed by mass spectrometry to identify novel interaction partners in cancer versus normal cells.

• Post-translational modification analysis: Phosphorylation-specific antibodies or phospho-proteomic approaches to identify cancer-specific modifications of BUB3.

• Genomic analysis: Correlating BUB3 mutations or copy number variations with chromosomal instability phenotypes across cancer databases.

Data integration across these methodologies can provide mechanistic insights into how BUB3 dysfunction contributes to chromosomal instability and cancer development, potentially revealing novel therapeutic targets.

How can researchers effectively validate the specificity of BUB3 antibodies?

Rigorous validation of BUB3 antibody specificity is essential for ensuring reliable experimental results. A comprehensive validation strategy should include multiple complementary approaches:

• Genetic controls:

  • siRNA/shRNA knockdown or CRISPR-Cas9 knockout of BUB3 should show corresponding reduction/elimination of signal

  • Overexpression of tagged BUB3 should show co-localization with antibody staining

  • Both approaches should be performed in multiple cell types to ensure consistent results

• Peptide competition assays:

  • Pre-incubation of antibody with the immunizing peptide (amino acids 1-328 of human BUB3) should abolish specific signals

  • Titration series of blocking peptide can determine antibody affinity parameters

• Cross-platform validation:

  • Consistent results across Western blotting, immunofluorescence, and immunoprecipitation

  • Molecular weight verification (37 kDa for BUB3) across different sample types

  • Subcellular localization pattern matching known BUB3 distribution (enriched at kinetochores during prometaphase)

• Positive control samples:

  • Include validated positive samples (MCF7, HL-60, HeLa cells, mouse tissues)

  • Compare staining patterns with published literature

• Batch-to-batch consistency testing:

  • Standardized positive controls should be included when testing new antibody lots

  • Quantitative comparison of signal intensity and specificity between lots

Documentation of all validation steps is essential for publications and reproducibility. Multiparametric validation provides strongest evidence for antibody specificity.

What are the key considerations for developing high-throughput screening assays using BUB3 antibodies?

Developing high-throughput screening (HTS) assays using BUB3 antibodies requires careful optimization of multiple parameters to ensure reliability, reproducibility, and sensitivity. HTS applications might include drug screening for compounds affecting mitotic checkpoint function or cancer cell sensitivity.

Critical considerations include:

• Assay platform selection:

  • ELISA-based detection systems offer quantitative BUB3 measurement with recommended antibody dilutions of 1:500-1:2000

  • Cell-based imaging platforms can assess BUB3 localization changes (1:50-1:200 dilution range)

  • AlphaLISA or similar homogeneous assays may offer higher throughput with less washing steps

• Signal optimization:

  • Signal-to-background ratio should exceed 5:1 for reliable hit detection

  • Z'-factor calculation should exceed 0.5 for robust assay performance

  • Positive and negative controls must show clear separation

• Antibody performance factors:

  • Batch consistency testing is essential for long screening campaigns

  • Stability assessment under HTS conditions (time, temperature, DMSO compatibility)

  • Secondary detection system optimization (fluorescent vs. chemiluminescent)

• Biological context:

  • Cell cycle synchronization may be necessary to reduce variability in BUB3 expression/localization

  • Time-course experiments may be required to capture dynamic BUB3 changes

  • Multiplexing with cell cycle markers can provide contextual data

• Data analysis pipeline:

  • Automated image analysis algorithms for localization studies

  • Statistical methods for hit identification and validation

  • Machine learning approaches for complex phenotypic patterns

Pilot screens with known modulators of the mitotic checkpoint should be conducted to validate assay performance before full-scale implementation. Orthogonal validation assays should be developed in parallel to confirm primary screening hits.

How can researchers address non-specific binding when using BUB3 antibodies?

Non-specific binding is a common challenge when working with antibodies. For BUB3 antibodies specifically, researchers should implement a systematic troubleshooting approach:

• Blocking optimization:

  • Test multiple blocking agents (BSA, casein, normal serum, commercial blockers)

  • Extend blocking time to 2 hours at room temperature

  • Include 0.1-0.3% Triton X-100 or 0.05% Tween-20 in blocking solutions

• Antibody dilution optimization:

  • Test multiple dilutions within the recommended ranges (1:500-1:2000 for WB, 1:50-1:200 for IF/ICC)

  • Prepare antibodies in fresh blocking solution

  • Consider longer incubation at lower concentrations (overnight at 4°C)

• Washing procedure enhancement:

  • Increase number and duration of washing steps

  • Add detergent (0.1% Tween-20) to washing buffers

  • Consider using isotonic PBS with precise pH calibration

• Sample preparation refinement:

  • Optimize fixation methods (paraformaldehyde vs. methanol) for IF applications

  • Ensure complete protein denaturation for Western blotting

  • Test multiple extraction buffers to improve signal-to-noise ratio

• Control experiments:

  • Include secondary-only controls to identify secondary antibody non-specific binding

  • Use isotype control antibodies at matching concentrations

  • Include peptide competition controls with the immunizing peptide sequence

If non-specific binding persists, affinity purification of the polyclonal antibody against the specific immunogen may improve specificity at the cost of some sensitivity reduction.

What experimental design strategies help resolve contradictory BUB3 data across different model systems?

When facing contradictory BUB3 data across different model systems, researchers should implement systematic experimental design strategies to resolve discrepancies:

• Standardization of detection methods:

  • Use identical antibody lots, dilutions, and protocols across all model systems

  • Process and analyze samples simultaneously when possible

  • Implement quantitative Western blotting with standard curves

• Biological context assessment:

  • Evaluate cell cycle synchronization status, as BUB3 function is cell cycle-dependent

  • Measure proliferation rates, which may affect BUB3 expression and localization

  • Consider genetic background differences affecting BUB3 regulation

• Cross-validation approaches:

  • Deploy multiple antibodies targeting different BUB3 epitopes

  • Employ orthogonal detection methods (mass spectrometry, RNA-seq)

  • Use genetic approaches (tagged BUB3 expression) alongside antibody-based detection

• Controlled variable manipulation:

  • Systematically vary experimental conditions one at a time

  • Test multiple positive control samples across systems (MCF7, HL-60, HeLa)

  • Conduct time-course experiments to capture dynamic changes

• Mechanistic investigation:

  • Examine post-translational modifications specific to each model system

  • Assess protein-protein interactions that may mask antibody epitopes

  • Investigate splice variants or isoforms with model-specific expression patterns

When publishing, researchers should explicitly document all experimental conditions and acknowledge model-specific differences rather than attempting to force agreement between disparate systems. Meta-analysis approaches combining data across multiple studies can help identify patterns explaining apparent contradictions.

How can BUB3 antibodies be utilized to study broad-target antibody development methodologies?

Recent advances in antibody research have revealed that certain rare antibodies can recognize multiple targets across different viruses while maintaining specificity . This concept can be applied to BUB3 research for developing next-generation research tools:

• Epitope-focused approach:

  • Identify conserved structural motifs within WD40 repeat domains of BUB3 and related proteins

  • Generate antibodies recognizing these shared structural elements

  • Validate cross-reactivity across BUB proteins (BUB1, BUB3, BUBR1) while maintaining specificity against unrelated proteins

• Application of LIBRA-seq technology:

  • The LIBRA-seq approach (Linking B-cell Receptor to Antigen Specificity through sequencing) developed at Vanderbilt University Medical Center can be adapted to identify rare B-cells producing broadly-reactive antibodies against conserved mitotic checkpoint proteins

  • This method enables mapping of amino acid sequences that make up reactive portions of antibodies and matching them to specific antigens

  • For BUB3 research, this could accelerate identification of antibodies recognizing functionally important domains

• Multi-target validation strategy:

  • Employ comprehensive validation panels including BUB3 alongside structurally related proteins

  • Utilize both positive and negative controls to define the specificity boundary

  • Document cross-reactivity profiles to enable informed experimental design

• Therapeutic potential assessment:

  • Evaluate whether broadly-reactive anti-BUB3 antibodies could target multiple cancer-associated mitotic checkpoint proteins

  • Investigate potential for developing antibody therapies targeting conserved domains in mitotic checkpoint proteins overexpressed in cancers

  • Assess off-target effects using proteome-wide binding assays

The development of such broadly-reactive yet specific antibodies could significantly advance research into mitotic checkpoint protein families and their role in cancer development.

How does HLA genotype influence antibody responses in research involving immunization with BUB3?

Research on antibody responses to various antigens has demonstrated that HLA class II alleles significantly influence antibody development . This has important implications for BUB3 antibody production and research:

• HLA association with antibody production:

  • Strong associations exist between specific HLA class II alleles and antibody responses to various antigens

  • HLA-DRB103:01 and HLA-DQB102:01 are associated with enhanced antibody responses, while HLA-DRB1*01:01 shows negative association with certain antibody responses

  • These associations should be considered when developing immunization strategies for BUB3 antibody production

• Experimental design considerations:

  • When generating BUB3 antibodies in animal models, selecting optimal epitopes that account for MHC presentation efficiency can improve outcomes

  • For human studies, stratifying analysis by HLA genotype may explain variability in immune responses to BUB3-derived peptides

  • Multiplexing approaches examining antibody responses to multiple epitopes simultaneously may reveal HLA-dependent recognition patterns

• Technical applications:

  • Custom antibody development services should consider HLA/MHC compatibility when designing immunization protocols

  • Pooled antibody approaches may overcome HLA-restricted response limitations

  • Epitope mapping should account for potential HLA-based presentation biases

• Translational implications:

  • Understanding HLA influence on anti-BUB3 responses could inform personalized immunotherapy approaches targeting mitotic checkpoint proteins in cancer

  • Vaccine design incorporating multiple BUB3 epitopes could overcome HLA restriction barriers

  • Patient stratification based on HLA genotype might predict response to BUB3-targeted therapies

This HLA-focused approach represents an advanced consideration in BUB3 antibody development that could significantly improve antibody quality and consistency for research applications.